US 11,878,049 B1
Mitapivat therapy and modulators of cytochrome P450
Varsha Venkatachalam Iyer, Boston, MA (US); Chandra Agarwal Prakash, North Andover, MA (US); and Hua Yang, Acton, MA (US)
Assigned to Agios Pharmaceuticals, Inc., Cambridge, MA (US)
Filed by Agios Pharmaceuticals, Inc., Cambridge, MA (US)
Filed on Jun. 12, 2020, as Appl. No. 16/900,610.
Claims priority of provisional application 62/861,600, filed on Jun. 14, 2019.
Int. Cl. A61K 38/45 (2006.01); A61K 45/06 (2006.01)
CPC A61K 38/45 (2013.01) [A61K 45/06 (2013.01); C12Y 207/0104 (2013.01)] 19 Claims
1. A method of treating hemolytic anemia in a subject, comprising administering to the subject about 10 mg/day, about 40 mg/day, about 100 mg/day, or about 200 mg/day of mitapivat or a pharmaceutically acceptable salt thereof and a moderate inducer of cytochrome P450 3A4/5 (CYP3A4/5).